Add thelocalreport.in As A Trusted Source
Drug-resistant varieties of common fungi Candida auris Scientists warn in a new commentary that the virus is increasing in virulence and spreading around the world.
Fungal infections affect nearly 6.5 million people every year, and even if no measures are taken, the mortality rate is as high as over 50% antifungal agent treat.
Candida auris is an invasive yeast that can cause fatal infectionEspecially people with weakened immune systems.
It was first discovered in the ear canal of a patient in Japan in 2009 and quickly spread to many countries, including India, where it was identified as a major public health threat in 2014.
A new review of research reveals several unique characteristics of the fungus that allow it to spread rapidly. Candida auris has been found in at least 61 countries on six continents.
The study notes that the fungus is rapidly becoming resistant to drugs due to its ability to switch from a yeast-like growth form to a filament-driven form of transmission. It also contains cell wall proteins that allow it to stick to and colonize human skin “like glue.”
“Skin colonization 100 ears This is an important medical issue because colonized patients may facilitate nosocomial and nosocomial transmission 100 ears ” The study was published in Microbiology and Molecular Biology Reviews, point out.
The fungus is equipped with “efflux pumps” on its cell membrane that clear it out before antifungal drugs can kill it. It also sticks together to form a sticky biofilm layer on the surface, making it difficult for drugs to penetrate.
It’s unclear whether the fungus has other ways of resisting the drugs, the study said. “Diagnosed as 100 ears Infections are often hampered by misidentification, leading to delays in initiating appropriate antifungal therapy,” the review explains.
“Taken together, these data highlight the need to develop novel antifungal agents with broad-spectrum activity against human fungal pathogens, improve diagnostic tests, and develop immune- and vaccine-based adjunctive modalities to treat high-risk patients.”
The review calls for increased efforts to increase awareness of fungal diseases through better surveillance mechanisms, especially in resource-poor countries. It noted that three new drugs currently in clinical trials may soon be used to treat this fungal infection.